Form 4: Labcorp CFO Granted Stock Options, Restricted Stock Units

Labcorp Holdings Inc.'s Chief Financial Officer, Julia Aijun Wang, was granted 7,100 non-qualified stock options and 2,350 restricted stock units on February 10, 2026.

Summary

• Julia Aijun Wang, Chief Financial Officer and EVP of Labcorp Holdings Inc. (LH), received equity compensation on February 10, 2026.
• The compensation includes a grant of 7,100 non-qualified stock options with an exercise price of $284.5 per share.
• These stock options were granted under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan and will vest in three equal annual installments starting February 10, 2027, expiring on February 09, 2036.
• Additionally, 2,350 Restricted Stock Units (RSUs) were granted, each representing the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• The RSUs will vest in three equal annual installments beginning on February 10, 2027.
• Following these transactions, Ms. Wang beneficially owns 7,100 non-qualified stock options and an aggregate of 5,824 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine but positive development, indicating continued executive alignment with shareholder interests through equity compensation, which is generally seen as a healthy governance practice.

Positives

• The grant of equity compensation aligns the Chief Financial Officer's incentives with long-term shareholder value.
• The compensation package is part of a structured incentive plan, indicating a commitment to executive retention and performance.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedules of the granted equity.

Industry Context

StockSavvy.ai notes that equity grants are a common practice to align executive incentives with shareholder interests in the healthcare diagnostics industry, promoting long-term commitment and performance.

Comparison to Industry Standards

• StockSavvy.ai observes that grants of stock options and restricted stock units are standard executive compensation practices across various industries, including healthcare.
• Companies like Quest Diagnostics (DGX) and DaVita Inc. (DVA) also utilize similar equity-based incentives for their executives to promote long-term performance and retention.
• The specific number of units granted is typically benchmarked against peer group compensation data and individual performance metrics within the healthcare services sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants are designed to align the interests of the Chief Financial Officer with those of shareholders, potentially leading to improved long-term performance.
• Employees: The use of an omnibus incentive plan suggests a structured approach to compensation that could extend to other key employees, fostering a performance-driven culture.

Next Steps

• The granted non-qualified stock options and restricted stock units will vest in three equal annual installments beginning February 10, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of equity compensation to a key executive and does not provide new fundamental information that would alter an investment thesis. It reflects standard practice for aligning executive incentives with long-term shareholder value, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Labcorp Holdings Inc., LH, Julia Aijun Wang, CFO, Stock Options, Restricted Stock Units, Equity Compensation, Insider Transaction, Executive Compensation